Thermo Fisher Scientific揭示Q数字PCR系统，用于遗传分析能力和更高研究的创新
Thermo Fisher Scientific揭示Q数字PCR系统，用于遗传分析能力和更高研究的创新
dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy oncology development and other research applications because its absolute quantification enables higher accuracy and precision. Thermo Fisher recently acquired Combinati and its cutting-edge dPCR technology to rapidly develop and commercialize it alongside an expanding portfolio of assays.
"Thermo Fisher Scientific is committed to innovation and providing the best technologies for our customers and help them accelerate innovation in areas including cancer research, rare diseases, and more. QuantStudio Absolute Q Digital PCR System is a much-needed solution in biotech and research-academia space,” said Amit Chopra, managing director, India, and South Asia, Thermo Fisher Scientific.
“The device overcomes the existing challenges of precision, operation, and turnaround time to provide an industry-best dPCR platform," added Amit.
Unlike complex, multi-instrument workflows required for traditional dPCR, the QuantStudio Absolute Q System uses microfluidic array technology and simplified workflows, designed to improve data accuracy and consistency. The device supports the pharmaceutical fraternity in innovating disease management, advancing significantly in generating consistent and accurate data.
“QuantStudio Absolute Q solution is a fast and simple workflow that offers high-quality data with minimum hands-on time. It integrates all the necessary steps for dPCR—digitization, thermal cycling, and data acquisition—into a single instrument. The dPCR is already in use for longitudinal monitoring of cancer-driving mutations in liquid biopsy and precise quantification of gene inserts for cell therapy development,” said Kapil Sood, senior director, Life Sciences Solutions, Thermo Fisher Scientific
填写下面的表格，我们将向您发送PDF版本的电子邮件“ Thermo Fisher Scientific揭示了Q数字PCR系统，用于遗传分析能力和更高研究的创新”
Thermo Fisher科学，服务科学领域的领导者已引入了应用生物系统QuantStudio绝对Q-数字PCR系统，第一个完全集成的数字PCR（DPCR）系统旨在在90分钟内提供高度准确，一致的结果。
DPCR已迅速成为肿瘤，细胞和基因治疗肿瘤学发展和其他研究应用中核酸定量的标准，因为其绝对定量可实现更高的准确性和精度。Thermo Fisher最近收购了Combinati及其尖端DPCR技术，以快速开发和商业化，并在扩大的测定中进行投资组合。
“ Thermo Fisher Scientific致力于创新并为我们的客户提供最佳技术，并帮助他们加速在包括癌症研究，稀有疾病等领域的创新。QuantStudio Absolute Q Digital PCR系统是生物技术和研究的急需解决方案 -学术空间，”阿米特·乔普拉（Amit Chopra），印度董事总经理和南亚，Thermo Fisher Scientific。
“该设备克服了精确，操作和周转时间的现有挑战，以提供行业最好的DPCR平台。”阿米特。
与传统DPCR所需的复杂的多功能仪器工作流不同，QuantStudio绝对Q系统使用微流体阵列技术和简化的工作流，旨在提高数据准确性和一致性。该设备在创新疾病管理方面支持药物兄弟会，在产生一致和准确的数据方面显着推进。
“ QuantStudio绝对Q解决方案是一个快速而简单的工作流程，可提供最小动手时间的高质量数据。它整合了DPCR的所有必要步骤 - 数量化，热循环和数据采集 - 构成了单个仪器。DPCR已经用于纵向监测液体活检中的癌症驱动突变，并精确地定量了基因插入物进行细胞疗法的发育。Kapil Sood，热科学解决方案高级主任，Thermo Fisher Scientific
